01—Abstract
Summary
Summary of the 10-Q filed May 6, 2025. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals Inc. reported its first-quarter 2025 financial results, showing a slight increase in total revenues to $2.77 billiona, up 3% year-over-year, primarily driven by the sustained performance of TRIKAFTA/KAFTRIO and the initial contributions from its new cystic fibrosis (CF) medicine, ALYFTREK.
However, net income saw a significant decline of 41% to $646.3 million, compared to $1.1 billionb in the prior year. This decrease was largely influenced by a substantial $379 million intangible asset impairment charge related to the discontinuation of the VX-264 clinical program for type 1 diabetes, and a decrease in acquired in-process research and development (AIPR&D) expenses. The company continues to invest heavily in research and development, with expenses rising 24% year-over-year, reflecting advancements across its diverse pipeline, including treatments for sickle cell disease (SCD), acute pain, and various rare diseases.
The launch of JOURNAVX for acute pain has shown early traction with over 20,000 prescriptions written within its first two months. Despite the decrease in net income, Vertex maintains a strong liquidity position with over $11.3 billionc in cash, cash equivalents, and marketable securities, supporting ongoing operations and strategic investments.
02—Key points
Key Highlights
- Total revenues increased 3% year-over-year to $2.77 billion, driven by TRIKAFTA/KAFTRIO and ALYFTREK.
- Net income decreased 41% to $646.3 million, impacted by a $379 million intangible asset impairment charge for the VX-264 program.
- Research and development expenses increased 24% to $979.7 million, reflecting continued pipeline investment.
- Acquired in-process R&D expenses decreased significantly by 74% to $19.8 million.
- The company recorded a $379.0 million intangible asset impairment charge due to the discontinuation of the VX-264 clinical program for type 1 diabetes.
- Cash, cash equivalents, and marketable securities totaled $11.36 billion, indicating a strong liquidity position.
- The new acute pain medicine, JOURNAVX, generated over 20,000 prescriptions in its initial two months post-launch.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Vertex Pharmaceuticals Inc kept $0.23.
- Revenue$2.77B100.0%
- Cost of revenue−$363.0M13.1%
- Gross profit$2.41B86.9%
- Operating costs−$1.78B64.2%
- Operating income$630.1M22.7%
- Interest, other & tax$16.2M0.6%
- Net income$646.3M23.3%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 6, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $2.77B$2.69B | +3.0% |
| Cost of Revenue | $363.00M$342.60M | +6.0% |
| Gross Profit | $2.41B$2.35B | +2.5% |
| SG&A Expenses | $396.40M$342.70M | +15.7% |
| Operating Expenses | $2.14B$1.55B | +38.0% |
| Operating Income | $630.10M$1.14B | −44.7% |
| Net Income | $646.30M$1.10B | −41.2% |
| EPS (Basic) | $2.52$4.26 | −40.8% |
| EPS (Diluted) | $2.49$4.21 | −40.9% |
| Shares Outstanding (Basic) | 256.90M258.20M | −0.5% |
| Shares Outstanding (Diluted) | 259.50M261.10M | −0.6% |
05—Questions
Frequently Asked Questions
What was the primary driver of the decrease in net income for the quarter?
The primary driver for the significant decrease in net income was a $379.0 million intangible asset impairment charge recorded in the first quarter of 2025. This charge was a result of the discontinuation of the VX-264 clinical program for type 1 diabetes.
How is Vertex Pharmaceuticals diversifying its product portfolio beyond cystic fibrosis?
Vertex is actively expanding its portfolio with approved and pipeline treatments in areas such as sickle cell disease and transfusion-dependent beta thalassemia (e.g., CASGEVY), acute pain (e.g., JOURNAVX), and a broad range of other serious diseases including APOL1-mediated kidney disease, IgA nephropathy, type 1 diabetes, and myotonic dystrophy type 1.
What is the company's current financial liquidity and outlook?
Vertex Pharmaceuticals maintains a strong liquidity position with $11.36 billion in cash, cash equivalents, and marketable securities as of March 31, 2025. Management expects this liquidity, combined with operating profitability, to be sufficient to fund operations for at least the next twelve months.
How are research and development expenses trending, and what areas are they focused on?
Research and development expenses increased by 24% year-over-year to $979.7 million in the first quarter of 2025. This increase reflects ongoing investments in a diverse pipeline, including programs for cystic fibrosis, sickle cell disease, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and myotonic dystrophy type 1.
06—Continue